サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1737546

バイオシミラーモノクローナル抗体の世界市場

Biosimilar Monoclonal Antibody

出版日
ページ情報
英文 235 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.71円
バイオシミラーモノクローナル抗体の世界市場
出版日: 2025年05月30日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 235 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

バイオシミラーモノクローナル抗体の世界市場は2030年までに445億米ドルに達する

2024年に140億米ドルと推定されるバイオシミラーモノクローナル抗体の世界市場は、2024～2030年の分析期間においてCAGR 21.2%で成長し、2030年には445億米ドルに達すると予測されます。本レポートで分析したセグメントの一つであるアダリムマブは、CAGR23.7%を記録し、分析期間終了時には161億米ドルに達すると予測されます。ベバシズマブセグメントの成長率は、分析期間中CAGR 18.2%と推定されます。

米国市場は37億米ドルと推定、中国はCAGR 19.9%で成長予測

米国のバイオシミラーモノクローナル抗体市場は、2024年に37億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに68億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは19.9%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ19.7％と18.0％と予測されています。欧州では、ドイツがCAGR約14.3％で成長すると予測されています。

世界のバイオシミラーモノクローナル抗体市場- 主要動向と促進要因のまとめ

バイオシミラーモノクローナル抗体が標的生物学的製剤へのアクセス拡大において重要な役割を果たすようになったのはなぜか？

バイオシミラーモノクローナル抗体（mAbs）は、オリジネーターである生物学的製剤の有効性、安全性、臨床成績を大幅に低コストで再現できることから、世界のヘルスケアシステムにおいて戦略的重要性を増しています。生物学的製剤ががん、自己免疫疾患、慢性炎症性疾患の治療の中心的存在となるにつれ、ブロックバスターmAbsの特許切れにより、バイオシミラーに代わる製剤の市場が開かれ、コスト抑制の必要性と先端治療薬への患者アクセスの拡大の必要性の両方に対応しています。

低分子のジェネリック医薬品とは異なり、バイオシミラーmAbsは、臨床的に意味のある差異を伴わない高い類似性を示すために、厳格な分析的特性評価と臨床的バリデーションが行われます。その承認と商業化により、ヘルスケアプロバイダーは生物学的製剤に関連する支出を削減し、処方への組み入れを拡大し、公的・私的環境全体にわたって治療へのアクセスを改善することができます。関節リウマチ、乳がん、大腸がんなどの負担の大きい疾患領域では、バイオシミラーmAbsが生物学的製剤による治療の経済性を変革しつつあります。

薬事規制、製造規模、臨床的信頼性はどのように市場導入を加速しているのか？

EMAの確立されたパスウェイ、FDAの351（k）承認プロセス、WHOのガイダンスなど、合理化されたバイオシミラー規制の枠組みは、バイオシミラーmAbsの世界展開を支援するために成熟してきました。これらの枠組みは、本格的な有効性試験よりも広範な比較可能性試験に重点を置いており、開発の迅速化とコスト効率化を可能にしています。規制の収束もまた、市場横断的な承認を容易にし、世界な上市スケジュールを早めています。

上流の細胞株工学、下流の精製プロセス、分析プラットフォームの開発により、バイオシミラー医薬品の製造精度が向上し、開発のばらつきと製造コストが削減されています。同時に、市販後調査データと実臨床のエビデンスにより、バイオシミラーでの治療切り替えや治療開始に対する医師の信頼が強まっています。また、医療従事者の教育、利害関係者の関与、支払者のインセンティブにより、病院、腫瘍センター、専門クリニック全体で、処方者の連携と組織的な採用が進んでいます。

バイオシミラーmAbsの需要はどこで拡大し、どの治療領域が成長をリードしているか？

欧州は、バイオシミラーモノクローナル抗体の最大かつ最も成熟した市場であり、積極的なヘルスケア政策、各国のバイオシミラー採用目標、入札ベースの調達モデルなどに支えられています。北米は、特にトラスツズマブ、ベバシズマブ、アダリムマブ、リツキシマブのバイオシミラー導入後、加速度的に導入が進んでいます。アジア太平洋地域は、強力な製造基盤、政府主導のコスト削減プログラム、インド、韓国、中国、日本などの国々における生物製剤需要の高まりにより、高成長地域として浮上しています。

主要な治療分野としては、トラスツズマブ、ベバシズマブ、リツキシマブのバイオシミラー製剤がファーストラインやセカンドラインのプロトコールでオリジネーター製剤に取って代わりつつあるがん領域（特に乳がん、肺がん、大腸がん）が挙げられます。免疫領域では、インフリキシマブ、アダリムマブ、エタネルセプトのバイオシミラーが関節リウマチ、乾癬、炎症性腸疾患に広く使用されています。病院ベースの治療レジメン、専門薬局での販売、支払者主導の代替政策が、これらの高コストの疾患カテゴリーにおける市場規模の主な促進要因となっています。

バイオシミラーモノクローナル抗体市場の世界的成長の原動力は？

バイオシミラーMAbs市場の世界の成長は、生物学的製剤の低価格化と治療需要の拡大という2つの圧力によって促進されています。ヘルスケアシステムが慢性疾患や複雑な疾患を管理するための持続可能なモデルを模索する中、バイオシミラー医薬品は臨床的同等性が証明された競争力のある価格を提供しています。支払側のインセンティブ、支援的な規制、スイッチング・プロトコルの改善により、医療機関への受け入れが促進される一方、オリジネーターの特許切れにより新たな商機が広がり続けています。

戦略的パートナーシップ、共同開発契約、大規模な生物製剤製造施設への投資は、供給の信頼性と製品の差別化を支えています。また、市場関係者は、信頼と普及を加速するために、ターゲットを絞った医師教育、実臨床試験結果の追跡、マルチチャネル販売に取り組んでいます。バイオシミラーmAbsが治療アルゴリズムや償還スキームに組み込まれるにつれ、次の段階を形作る決定的な疑問が生じます。バイオシミラー医薬品業界は、価格競争力と製造の完全性を維持しながら、安全性、品質、臨床転帰を損なうことなく、高コストの生物学的製剤への世界のアクセスを拡大することができるのか？

セグメント

タイプ（アダリムマブ、ベバシズマブ、インフリキシマブ、リツキシマブ、トラスツズマブ、その他のタイプ）、適応症（がん、自己免疫疾患、その他の適応症）、エンドユーザー（病院、がん治療センター、その他のエンドユーザー）

調査対象企業の例（注目の43社）

  • Amgen Inc.
  • Biocon Biologics Ltd.
  • Biogen Inc.
  • Boehringer Ingelheim GmbH
  • Celltrion Healthcare Co., Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Fresenius Kabi AG
  • Henlius Biotech, Inc.
  • Merck & Co., Inc.
  • Mylan N.V.（now part of Viatris）
  • Novartis AG
  • Pfizer Inc.
  • Samsung Bioepis Co., Ltd.
  • Sandoz International GmbH
  • Teva Pharmaceutical Industries Ltd.
  • Alvotech
  • Apobiologix（Apotex Inc.）
  • Coherus BioSciences, Inc.
  • Formycon AG
  • Xbrane Biopharma AB

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP33562

Global Biosimilar Monoclonal Antibody Market to Reach US$44.5 Billion by 2030

The global market for Biosimilar Monoclonal Antibody estimated at US$14.0 Billion in the year 2024, is expected to reach US$44.5 Billion by 2030, growing at a CAGR of 21.2% over the analysis period 2024-2030. Adalimumab, one of the segments analyzed in the report, is expected to record a 23.7% CAGR and reach US$16.1 Billion by the end of the analysis period. Growth in the Bevacizumab segment is estimated at 18.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.7 Billion While China is Forecast to Grow at 19.9% CAGR

The Biosimilar Monoclonal Antibody market in the U.S. is estimated at US$3.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$6.8 Billion by the year 2030 trailing a CAGR of 19.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 19.7% and 18.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.3% CAGR.

Global Biosimilar Monoclonal Antibody Market - Key Trends & Drivers Summarized

Why Are Biosimilar Monoclonal Antibodies Becoming Pivotal in Expanding Access to Targeted Biologic Therapies?

Biosimilar monoclonal antibodies (mAbs) are gaining strategic importance in global healthcare systems due to their ability to replicate the efficacy, safety, and clinical performance of originator biologics at significantly lower costs. As biologics become central to the treatment of cancer, autoimmune diseases, and chronic inflammatory conditions, the expiration of patents on blockbuster mAbs has opened the market for biosimilar alternatives-addressing both cost containment imperatives and the need to widen patient access to advanced therapeutics.

Unlike generic small molecules, biosimilar mAbs undergo rigorous analytical characterization and clinical validation to demonstrate high similarity without clinically meaningful differences. Their approval and commercialization are enabling healthcare providers to reduce biologics-related expenditure, expand formulary inclusion, and improve therapy access across public and private settings. In high-burden disease areas like rheumatoid arthritis, breast cancer, and colorectal cancer, biosimilar mAbs are transforming the economics of biologic care.

How Are Regulatory Pathways, Manufacturing Scale, and Clinical Confidence Accelerating Market Uptake?

Streamlined biosimilar regulatory frameworks-such as the EMA’s well-established pathway, the FDA’s 351(k) approval process, and WHO guidance-have matured to support the global rollout of biosimilar mAbs. These frameworks focus on extensive comparability exercises rather than full-scale efficacy trials, enabling faster and cost-efficient development. Regulatory convergence is also facilitating cross-market approvals and accelerating global launch timelines.

Advancements in upstream cell-line engineering, downstream purification processes, and analytical platforms are improving biosimilar manufacturing precision, while reducing development variability and production costs. Simultaneously, post-marketing surveillance data and real-world evidence are reinforcing physician confidence in switching and initiating treatment with biosimilars. Provider education, stakeholder engagement, and payer incentives are also increasing prescriber alignment and institutional adoption across hospitals, oncology centers, and specialty clinics.

Where Is Demand for Biosimilar mAbs Expanding and Which Therapeutic Areas Are Leading Growth?

Europe remains the largest and most mature market for biosimilar monoclonal antibodies, supported by proactive healthcare policy, national biosimilar adoption targets, and tender-based procurement models. North America is witnessing accelerated uptake, particularly following the introduction of biosimilars for trastuzumab, bevacizumab, adalimumab, and rituximab. Asia-Pacific is emerging as a high-growth region with a strong manufacturing base, government-led cost-reduction programs, and rising biologics demand in countries such as India, South Korea, China, and Japan.

Leading therapeutic segments include oncology-particularly breast, lung, and colorectal cancers-where trastuzumab, bevacizumab, and rituximab biosimilars are displacing originator therapies in first- and second-line protocols. In immunology, biosimilars for infliximab, adalimumab, and etanercept are being widely used for rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Hospital-based treatment regimens, specialty pharmacy distribution, and payer-driven substitution policies are key drivers of market volume across these high-cost disease categories.

What Is Fueling the Global Growth of the Biosimilar Monoclonal Antibody Market?

The global growth of the biosimilar mAbs market is being fueled by the dual pressures of biologic drug affordability and therapeutic demand expansion. As healthcare systems seek sustainable models for managing chronic and complex diseases, biosimilars are offering competitive pricing with proven clinical equivalence. Payer incentives, supportive regulation, and improved switching protocols are facilitating institutional acceptance, while originator off-patent expirations continue to unlock new commercial opportunities.

Strategic partnerships, co-development deals, and investment in large-scale biologics manufacturing facilities are supporting supply reliability and product differentiation. Market players are also engaging in targeted physician education, real-world outcome tracking, and multi-channel distribution to accelerate trust and uptake. As biosimilar mAbs become embedded in treatment algorithms and reimbursement schemes, a defining question shapes the next phase: Can the biosimilar industry maintain pricing competitiveness and manufacturing integrity-while scaling global access to high-cost biologic therapies without compromising safety, quality, or clinical outcomes?

SCOPE OF STUDY:

The report analyzes the Biosimilar Monoclonal Antibody market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab, Other Types); Indication (Oncology, Autoimmune Diseases, Other Indications); End-User (Hospitals, Cancer Treatment Centers, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 43 Featured) -

  • Amgen Inc.
  • Biocon Biologics Ltd.
  • Biogen Inc.
  • Boehringer Ingelheim GmbH
  • Celltrion Healthcare Co., Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Fresenius Kabi AG
  • Henlius Biotech, Inc.
  • Merck & Co., Inc.
  • Mylan N.V. (now part of Viatris)
  • Novartis AG
  • Pfizer Inc.
  • Samsung Bioepis Co., Ltd.
  • Sandoz International GmbH
  • Teva Pharmaceutical Industries Ltd.
  • Alvotech
  • Apobiologix (Apotex Inc.)
  • Coherus BioSciences, Inc.
  • Formycon AG
  • Xbrane Biopharma AB

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Biosimilar Monoclonal Antibody - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Patent Expiry of Major Biologics Opens Market Opportunities for Biosimilar Monoclonal Antibodies
    • Cost Containment in Oncology and Autoimmune Therapies Drives Payer Support for Biosimilars
    • Regulatory Harmonization and Fast-Track Approvals Encourage Multinational Biosimilar Launches
    • Hospital Formularies and Physician Confidence Grow as Clinical Equivalence Is Proven for mAb Biosimilars
    • Expansion of Manufacturing Capabilities in Emerging Markets Lowers Production Cost for Biosimilar mAbs
    • Oncology, Rheumatology, and Gastroenterology Remain Key Therapeutic Areas for Biosimilar mAb Adoption
    • Education Initiatives Targeting Clinicians and Pharmacists Bolster Uptake of Monoclonal Biosimilars
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Biosimilar Monoclonal Antibody Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Biosimilar Monoclonal Antibody by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Biosimilar Monoclonal Antibody by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Biosimilar Monoclonal Antibody by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Adalimumab by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Adalimumab by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Adalimumab by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Bevacizumab by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Bevacizumab by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Bevacizumab by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Infliximab by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Infliximab by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Infliximab by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Rituximab by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Rituximab by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Rituximab by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Trastuzumab by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Trastuzumab by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Trastuzumab by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Cancer Treatment Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Cancer Treatment Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Cancer Treatment Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Autoimmune Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Autoimmune Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Autoimmune Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Biosimilar Monoclonal Antibody Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Biosimilar Monoclonal Antibody by Type - Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Biosimilar Monoclonal Antibody by Type - Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Biosimilar Monoclonal Antibody by Type - Percentage Breakdown of Value Sales for Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab and Other Types for the Years 2015, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Biosimilar Monoclonal Antibody by End-user - Hospitals, Cancer Treatment Centers and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Biosimilar Monoclonal Antibody by End-user - Hospitals, Cancer Treatment Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Biosimilar Monoclonal Antibody by End-user - Percentage Breakdown of Value Sales for Hospitals, Cancer Treatment Centers and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Biosimilar Monoclonal Antibody by Indication - Oncology, Autoimmune Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Biosimilar Monoclonal Antibody by Indication - Oncology, Autoimmune Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Biosimilar Monoclonal Antibody by Indication - Percentage Breakdown of Value Sales for Oncology, Autoimmune Diseases and Other Indications for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Biosimilar Monoclonal Antibody by Type - Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Biosimilar Monoclonal Antibody by Type - Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Biosimilar Monoclonal Antibody by Type - Percentage Breakdown of Value Sales for Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab and Other Types for the Years 2015, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Biosimilar Monoclonal Antibody by End-user - Hospitals, Cancer Treatment Centers and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Biosimilar Monoclonal Antibody by End-user - Hospitals, Cancer Treatment Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Biosimilar Monoclonal Antibody by End-user - Percentage Breakdown of Value Sales for Hospitals, Cancer Treatment Centers and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Biosimilar Monoclonal Antibody by Indication - Oncology, Autoimmune Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Biosimilar Monoclonal Antibody by Indication - Oncology, Autoimmune Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for Biosimilar Monoclonal Antibody by Indication - Percentage Breakdown of Value Sales for Oncology, Autoimmune Diseases and Other Indications for the Years 2015, 2025 & 2030
  • JAPAN
    • Biosimilar Monoclonal Antibody Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Biosimilar Monoclonal Antibody by Type - Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Biosimilar Monoclonal Antibody by Type - Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for Biosimilar Monoclonal Antibody by Type - Percentage Breakdown of Value Sales for Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab and Other Types for the Years 2015, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Biosimilar Monoclonal Antibody by End-user - Hospitals, Cancer Treatment Centers and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Biosimilar Monoclonal Antibody by End-user - Hospitals, Cancer Treatment Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Biosimilar Monoclonal Antibody by End-user - Percentage Breakdown of Value Sales for Hospitals, Cancer Treatment Centers and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Biosimilar Monoclonal Antibody by Indication - Oncology, Autoimmune Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Biosimilar Monoclonal Antibody by Indication - Oncology, Autoimmune Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Japan 15-Year Perspective for Biosimilar Monoclonal Antibody by Indication - Percentage Breakdown of Value Sales for Oncology, Autoimmune Diseases and Other Indications for the Years 2015, 2025 & 2030
  • CHINA
    • Biosimilar Monoclonal Antibody Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 68: China Recent Past, Current & Future Analysis for Biosimilar Monoclonal Antibody by Type - Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Biosimilar Monoclonal Antibody by Type - Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for Biosimilar Monoclonal Antibody by Type - Percentage Breakdown of Value Sales for Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab and Other Types for the Years 2015, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Biosimilar Monoclonal Antibody by End-user - Hospitals, Cancer Treatment Centers and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Biosimilar Monoclonal Antibody by End-user - Hospitals, Cancer Treatment Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: China 15-Year Perspective for Biosimilar Monoclonal Antibody by End-user - Percentage Breakdown of Value Sales for Hospitals, Cancer Treatment Centers and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Biosimilar Monoclonal Antibody by Indication - Oncology, Autoimmune Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Biosimilar Monoclonal Antibody by Indication - Oncology, Autoimmune Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: China 15-Year Perspective for Biosimilar Monoclonal Antibody by Indication - Percentage Breakdown of Value Sales for Oncology, Autoimmune Diseases and Other Indications for the Years 2015, 2025 & 2030
  • EUROPE
    • Biosimilar Monoclonal Antibody Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Biosimilar Monoclonal Antibody by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Biosimilar Monoclonal Antibody by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Biosimilar Monoclonal Antibody by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Biosimilar Monoclonal Antibody by Type - Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Biosimilar Monoclonal Antibody by Type - Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Biosimilar Monoclonal Antibody by Type - Percentage Breakdown of Value Sales for Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab and Other Types for the Years 2015, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Biosimilar Monoclonal Antibody by End-user - Hospitals, Cancer Treatment Centers and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Biosimilar Monoclonal Antibody by End-user - Hospitals, Cancer Treatment Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Biosimilar Monoclonal Antibody by End-user - Percentage Breakdown of Value Sales for Hospitals, Cancer Treatment Centers and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Biosimilar Monoclonal Antibody by Indication - Oncology, Autoimmune Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Biosimilar Monoclonal Antibody by Indication - Oncology, Autoimmune Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Europe 15-Year Perspective for Biosimilar Monoclonal Antibody by Indication - Percentage Breakdown of Value Sales for Oncology, Autoimmune Diseases and Other Indications for the Years 2015, 2025 & 2030
  • FRANCE
    • Biosimilar Monoclonal Antibody Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 89: France Recent Past, Current & Future Analysis for Biosimilar Monoclonal Antibody by Type - Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Biosimilar Monoclonal Antibody by Type - Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for Biosimilar Monoclonal Antibody by Type - Percentage Breakdown of Value Sales for Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab and Other Types for the Years 2015, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Biosimilar Monoclonal Antibody by End-user - Hospitals, Cancer Treatment Centers and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Biosimilar Monoclonal Antibody by End-user - Hospitals, Cancer Treatment Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: France 15-Year Perspective for Biosimilar Monoclonal Antibody by End-user - Percentage Breakdown of Value Sales for Hospitals, Cancer Treatment Centers and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Biosimilar Monoclonal Antibody by Indication - Oncology, Autoimmune Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Biosimilar Monoclonal Antibody by Indication - Oncology, Autoimmune Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: France 15-Year Perspective for Biosimilar Monoclonal Antibody by Indication - Percentage Breakdown of Value Sales for Oncology, Autoimmune Diseases and Other Indications for the Years 2015, 2025 & 2030
  • GERMANY
    • Biosimilar Monoclonal Antibody Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Biosimilar Monoclonal Antibody by Type - Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Biosimilar Monoclonal Antibody by Type - Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for Biosimilar Monoclonal Antibody by Type - Percentage Breakdown of Value Sales for Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab and Other Types for the Years 2015, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Biosimilar Monoclonal Antibody by End-user - Hospitals, Cancer Treatment Centers and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Biosimilar Monoclonal Antibody by End-user - Hospitals, Cancer Treatment Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Germany 15-Year Perspective for Biosimilar Monoclonal Antibody by End-user - Percentage Breakdown of Value Sales for Hospitals, Cancer Treatment Centers and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Biosimilar Monoclonal Antibody by Indication - Oncology, Autoimmune Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Biosimilar Monoclonal Antibody by Indication - Oncology, Autoimmune Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Germany 15-Year Perspective for Biosimilar Monoclonal Antibody by Indication - Percentage Breakdown of Value Sales for Oncology, Autoimmune Diseases and Other Indications for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Biosimilar Monoclonal Antibody by Type - Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Biosimilar Monoclonal Antibody by Type - Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for Biosimilar Monoclonal Antibody by Type - Percentage Breakdown of Value Sales for Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab and Other Types for the Years 2015, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Biosimilar Monoclonal Antibody by End-user - Hospitals, Cancer Treatment Centers and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Biosimilar Monoclonal Antibody by End-user - Hospitals, Cancer Treatment Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Italy 15-Year Perspective for Biosimilar Monoclonal Antibody by End-user - Percentage Breakdown of Value Sales for Hospitals, Cancer Treatment Centers and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Biosimilar Monoclonal Antibody by Indication - Oncology, Autoimmune Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Biosimilar Monoclonal Antibody by Indication - Oncology, Autoimmune Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Italy 15-Year Perspective for Biosimilar Monoclonal Antibody by Indication - Percentage Breakdown of Value Sales for Oncology, Autoimmune Diseases and Other Indications for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Biosimilar Monoclonal Antibody Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 116: UK Recent Past, Current & Future Analysis for Biosimilar Monoclonal Antibody by Type - Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Biosimilar Monoclonal Antibody by Type - Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: UK 15-Year Perspective for Biosimilar Monoclonal Antibody by Type - Percentage Breakdown of Value Sales for Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab and Other Types for the Years 2015, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Biosimilar Monoclonal Antibody by End-user - Hospitals, Cancer Treatment Centers and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Biosimilar Monoclonal Antibody by End-user - Hospitals, Cancer Treatment Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: UK 15-Year Perspective for Biosimilar Monoclonal Antibody by End-user - Percentage Breakdown of Value Sales for Hospitals, Cancer Treatment Centers and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Biosimilar Monoclonal Antibody by Indication - Oncology, Autoimmune Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Biosimilar Monoclonal Antibody by Indication - Oncology, Autoimmune Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: UK 15-Year Perspective for Biosimilar Monoclonal Antibody by Indication - Percentage Breakdown of Value Sales for Oncology, Autoimmune Diseases and Other Indications for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 125: Rest of Europe Recent Past, Current & Future Analysis for Biosimilar Monoclonal Antibody by Type - Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Europe Historic Review for Biosimilar Monoclonal Antibody by Type - Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Europe 15-Year Perspective for Biosimilar Monoclonal Antibody by Type - Percentage Breakdown of Value Sales for Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab and Other Types for the Years 2015, 2025 & 2030
    • TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Biosimilar Monoclonal Antibody by End-user - Hospitals, Cancer Treatment Centers and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Europe Historic Review for Biosimilar Monoclonal Antibody by End-user - Hospitals, Cancer Treatment Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Europe 15-Year Perspective for Biosimilar Monoclonal Antibody by End-user - Percentage Breakdown of Value Sales for Hospitals, Cancer Treatment Centers and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Biosimilar Monoclonal Antibody by Indication - Oncology, Autoimmune Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Biosimilar Monoclonal Antibody by Indication - Oncology, Autoimmune Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 15-Year Perspective for Biosimilar Monoclonal Antibody by Indication - Percentage Breakdown of Value Sales for Oncology, Autoimmune Diseases and Other Indications for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Biosimilar Monoclonal Antibody Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 134: Asia-Pacific Recent Past, Current & Future Analysis for Biosimilar Monoclonal Antibody by Type - Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Asia-Pacific Historic Review for Biosimilar Monoclonal Antibody by Type - Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Asia-Pacific 15-Year Perspective for Biosimilar Monoclonal Antibody by Type - Percentage Breakdown of Value Sales for Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab and Other Types for the Years 2015, 2025 & 2030
    • TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Biosimilar Monoclonal Antibody by End-user - Hospitals, Cancer Treatment Centers and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Asia-Pacific Historic Review for Biosimilar Monoclonal Antibody by End-user - Hospitals, Cancer Treatment Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Asia-Pacific 15-Year Perspective for Biosimilar Monoclonal Antibody by End-user - Percentage Breakdown of Value Sales for Hospitals, Cancer Treatment Centers and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Biosimilar Monoclonal Antibody by Indication - Oncology, Autoimmune Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Biosimilar Monoclonal Antibody by Indication - Oncology, Autoimmune Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 15-Year Perspective for Biosimilar Monoclonal Antibody by Indication - Percentage Breakdown of Value Sales for Oncology, Autoimmune Diseases and Other Indications for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 143: Rest of World Recent Past, Current & Future Analysis for Biosimilar Monoclonal Antibody by Type - Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of World Historic Review for Biosimilar Monoclonal Antibody by Type - Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of World 15-Year Perspective for Biosimilar Monoclonal Antibody by Type - Percentage Breakdown of Value Sales for Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab and Other Types for the Years 2015, 2025 & 2030
    • TABLE 146: Rest of World Recent Past, Current & Future Analysis for Biosimilar Monoclonal Antibody by End-user - Hospitals, Cancer Treatment Centers and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of World Historic Review for Biosimilar Monoclonal Antibody by End-user - Hospitals, Cancer Treatment Centers and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of World 15-Year Perspective for Biosimilar Monoclonal Antibody by End-user - Percentage Breakdown of Value Sales for Hospitals, Cancer Treatment Centers and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 149: Rest of World Recent Past, Current & Future Analysis for Biosimilar Monoclonal Antibody by Indication - Oncology, Autoimmune Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of World Historic Review for Biosimilar Monoclonal Antibody by Indication - Oncology, Autoimmune Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Rest of World 15-Year Perspective for Biosimilar Monoclonal Antibody by Indication - Percentage Breakdown of Value Sales for Oncology, Autoimmune Diseases and Other Indications for the Years 2015, 2025 & 2030

IV. COMPETITION